ベンツイミダゾール誘導体の抗ウイルス性(第4報)ビスベンツイミダゾール誘導体その2

抄録

The inhibitory effect of bisbenzimidazole derivatives on poliovirus and adenoirus replication was investigated by the tube method. Among the compounds tested, 1, 3-bis(2-benzimidazolyl)propane (IV), 1, 3-bis(5 or 6-nitro-2-benzimidazolyl)propane (VI), 1, 3-bis(2-benzimidazolyl)-1, 2, 3-trihydroxypropane (VIII), 1, 4-bis(2-benzimidazolyl)butane (XII), 1, 4-bis(5 or 6-chloro-2-benzimidazolyl)butane (XIV), 1, 4-bis (5 or 6-methoxy-2-benzimidazolyl)butane (XVI), 1, 4-bis(2-benzimidazolyl)-1, 2, 3, 4-tetrahydroxybutane (XVII), 1, 4-bis(5 or 6-methoxy-2-benzimidazolyl)-1, 2, 3, 4-tetrahydroxybutane (XX), 1, 5-bis(5 or 6-methyl-2-benzimidazolyl)pentane (XXII), 1, 6-bis(5 or 6-methyl-2-benzimidazolyl)hexane (XXVI), 1, 6-bis(5 or 6-nitro-2-benzimidazolyl)hexane (XXVIII), and 1, 6-bis(5 or 6-methoxy-2-benzimidazolyl)hexane (XXIX) exerted a slight inhibition on the cytopathic effect of poliovirus, but did not show any antiviral activity against adenovirus. At the concentration of maximum nontoxic dose, IV, VI, VIII, XII, XVI, XVII, XX, XXII, and XXIX inhibited the plaque formation by poliovirus to 86.6%, 56.3%, 58.5%, 56.9%, 69.8%. 69.9%, 66.4%, 72.2%, and 65.6%, respectively. Compounds IV, XVI, XVII, and XXII also reduced the yield of intracellular virus and the incorporation of ¹⁴C-uridine into acid-insoluble material in HeLa cells infected with poliovirus.